What is a potential side effect of erythropoietin (EPO) in a patient with Chronic Kidney Disease (CKD) and anemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Erythropoietin in CKD Patients with Anemia

Hypertension is the most common side effect of erythropoietin (EPO) therapy in CKD patients, occurring in approximately 23% of treated patients. 1

Major Side Effects of Erythropoietin

Hypertension

  • Occurs in approximately 23% of CKD patients treated with EPO 1
  • Mechanism involves:
    • Increased vascular wall reactivity
    • Hemodynamic changes related to increasing red blood cell mass
    • Possible increase in the ratio of plasma endothelin to proendothelin 1
    • Elevated cytosolic ionic calcium and nitric oxide resistance 1
  • Management:
    • Blood pressure monitoring, particularly during initiation of therapy
    • Initiation or increase of antihypertensive medications
    • Intensified ultrafiltration if extracellular volume expansion is present
    • Reduction in EPO dose if rapid hemoglobin rise occurs 1

Seizures

  • Can occur during EPO therapy, especially with hypertensive encephalopathy 1
  • Not associated with EPO dose or rate of hemoglobin increase
  • More common with higher doses used in earlier years of EPO therapy 1
  • Often associated with rapid increases in blood pressure 1
  • Management:
    • EPO should be discontinued if hypertensive encephalopathy with seizures occurs until clinical stability is achieved 1

Other Potential Side Effects

  • Increased clotting tendency/thrombosis (though evidence suggests no increased need for surveillance) 1
  • Pure red cell aplasia (PRCA) - rare but serious complication due to neutralizing antibodies 1
  • Hyperkalemia (though recent data indicate incidence is not significantly higher) 1

Analyzing the Multiple Choice Options

Looking at the options provided in the question:

  • A. Intracranial hyperplasia - Not a documented side effect of EPO
  • B. Hypotension - Opposite of the most common side effect (hypertension)
  • C. Hypercalcemia - Not a documented side effect of EPO
  • D. Osteoporosis - Not a documented side effect of EPO
  • E. Seizures - Documented side effect, especially in association with hypertensive encephalopathy 1

Based on the evidence from the National Kidney Foundation guidelines, seizures are a recognized side effect of erythropoietin therapy in CKD patients, particularly when associated with hypertensive encephalopathy. While hypertension is the most common side effect, seizures represent a serious adverse effect that can occur during treatment.

Therefore, among the given options, seizures (option E) is the correct answer as it is a documented side effect of erythropoietin therapy in CKD patients with anemia.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.